Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Cannabis Use Disorder
NCT07468552Phase 2Not yet recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of tirzepatide in cannabis use disorder (CUD), sponsored by National Institute on Drug Abuse. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT07468552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468552.